Nancy Wexler talks about her journey with the New York Times. See the full article here: https://www.nytimes.com/2026/06/11/science/researcher-huntingtons-disease-wexler.html?unlocked_article_code=1.pVA.mfHg.2dTUKo0G6h9B&smid=em-share
Update: Improvement in Huntington’s disease patients in Skyhawk Therapeutics trial
"Skyhawk Therapeutics announces twelve-month results from Phase 1/2 clinical trial of SKY-0515 in Huntington’s disease." See the full article here: https://www.hda.org.uk/news/improvement-in-huntingtons-disease-patients-in-skyhawk-therapeutics-trial/?fbclid=IwY2xjawSK0ZJleHRuA2FlbQIxMABicmlkETF2blNzVmZwUkdKNVBLaTVIc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHhgg2aNTt20l3b9AQ5wZn0niDF1zyTU4PJfEHdmlbVoOgs1eU3cBBuwLBcVo_aem_Rm5hVdb90gjJJPjY_tmQgQ
Columbia News: Interview with Nancy Wexler
Nancy Wexler did an interview with the Columbia News: Devoting Your Life to Studying the Disease That Afflicts You See the full interview here: https://news.columbia.edu/news/devoting-your-life-studying-disease-afflicts-you?bbeml=tp-kOgnhSY2TESsVKneKkvHVw.jRdNdjYVHzk-JYNf-9o5BLg.rIa8dzWPW2UmdklL1N13fTA.l140HAKQppE27gsGn6O49qw
The Huntington's Disease Foundation announced the official release for Nancy S. Wexler's memoir. The book is now available! You can purchase the book directly from the publisher, the Cold Spring…
FDA meets with uniQure about AMT130
The FDA met with uniQure on March 2, 2026 about the future of AMT 130. View full article here: https://www.hdreach.org/file_download/inline/7dd4837d-98b5-44b9-b71e-552b01e021cb
HDSA Letter to HD Community
View full article here: https://app.donorview.com/communication/view?prm=tqITQp5N0w3BYK94HwsDgB1WosiCtMQprdkQ_yrGx2fJMJ-MHmXx2ZGQ8DNYz-ID95O7AnDE0R-1zUQD0mvQFQ_NKHNEzi1X7SqAthLR9N_6HdDM3p8Qvm9cOrcdnICjOjy892xIEGYZKmqF0pgrxwRXloZ7lWYkeDtjlQh8tvoFlDStnFAZuLVd0BEGVwWNSk2WuE0cBMycymo95ifdKxsmji6IxOARARWGWIEM3go1
Rare Disease Week — February 23–27, 2026
From Action Alert: Rare Disease Week is right around the corner, and this is a key opportunity to show up for the Huntington’s disease community and amplify our collective voice.…
CIRM approves new $100M plan to accelerate genetic therapies rare disease patients
The California Institute for Regenerative Medicine (CIRM) has launched the $100 million RAPID program to accelerate the development and delivery of platform-based genetic therapies for rare diseases. Building on the…
Skyhawk Therapeutics Announces Nine Month Interim Results
A press release from Skyhawk Therapeutics announces nine month interim results in patients from its Phase 1 clinical trial of SKY-0515 as a treatment for Huntington’s Disease. See the full…
Menifee City Disabilities Fair
The Menifee City Disabilities Fair, sponsored by the city of Menifee November 8th, 2025: UCI HD-CARE board member Leslie Frias was there to raise awareness for Huntington Disease research at…